BioSpace News Archive

Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.

Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix drug discovery platform, announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology.

Mogrify Limited, a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round.

HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment, and requires vastly lower dosing than current COVID-19 vaccines

Omeros Corporation announced that the Centers for Disease Control and Prevention has approved an International Classification of Diseases diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

The MS Society of Canada will host its annual MS Walk throughout the month of May – MS Awareness Month — to raise awareness for an important cause in a safe way that will respect public health guidelines.

Seasoned manufacturing executive brings experience managing multi-billion dollar consumer product lines to scale biofacturing platform for commercial markets

Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021.

Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab